Keytruda 100mg/4ml

Keytruda (pembrolizumab) 100 mg/4 mL concentrate for solution for infusion. Single-use vial. For intravenous infusion only after dilution. Indications: KEYTRUDA contains the active substance pembrolizumab, which is a monoclonal antibody. KEYTRUDA works by helping your immune system fight cancer. KEYTRUDA is used in adults to treat: melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, urothelial carcinoma, head and neck squamous cell carcinoma, renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancers (colorectal, endometrial, gastric, small intestine, biliary tract), esophageal carcinoma, triple-negative breast cancer, endometrial carcinoma, cervical cancer, gastric or gastroesophageal junction adenocarcinoma, and biliary tract carcinoma. KEYTRUDA is used in children and adolescents: aged 3 years and over to treat classical Hodgkin lymphoma; aged 12 years and over to treat melanoma. Patients receive KEYTRUDA when cancer has spread or cannot be removed by surgery. Patients may receive KEYTRUDA after surgery to help prevent cancer recurrence (adjuvant treatment) or before surgery (neoadjuvant treatment). Contraindications: Do not use KEYTRUDA if you are allergic to pembrolizumab or any other ingredients. Precautions: Before receiving KEYTRUDA, talk to your doctor or pharmacist. KEYTRUDA can cause serious side effects including immune-mediated reactions affecting lungs, intestines, liver, kidneys, hormone glands, nervous system, skin, and other organs. Monitor for new or worsening symptoms. Pregnancy and breastfeeding: Do not use KEYTRUDA if pregnant unless specifically recommended by your doctor. KEYTRUDA may harm your unborn baby or cause death. Use effective contraception during treatment and for at least 4 months after the last dose. Do not breastfeed during treatment. Driving and using machines: KEYTRUDA has minor influence on ability to drive or use machines. Dizziness, fatigue, or weakness are possible side effects. Do not drive or use machines unless you are sure you feel well. Administration: KEYTRUDA will be given in a hospital or clinic under supervision of an experienced doctor. Recommended dose in adults is 200 mg every 3 weeks or 400 mg every 6 weeks. In children/adolescents: 2 mg/kg body weight (up to maximum 200 mg) every 3 weeks. Given as IV infusion over approximately 30 minutes. Composition: Active substance: pembrolizumab. One vial contains 100 mg pembrolizumab in 4 mL. Each mL contains 25 mg pembrolizumab. Other ingredients: L-histidine, L-histidine hydrochloride monohydrate, sucrose, polysorbate 80, water for injections. Package: 1 vial Warning: Read the package leaflet carefully before use. This summary is not complete. Always consult full prescribing information and your healthcare provider. Regulatory Disclaimer: This listing is for informational purposes only. Supply restricted to authorized channels where legally permitted. Consult your oncologist for individualized treatment decisions.